Global Life Sciences Cluster Report 2011 - Jones Lang LaSalle

More documents

Recommendations

Info

China, India, Indonesia and Singapore Asia Pacific In this section we discuss four clusters in the Asia Pacific region that are emerging at the forefront of industry activity. Emerging clusters in Asia have extremely high growth potential for a variety of reasons. Factors such as growing economies, large populations, rising personal income levels and progressive political policies encourage growth and direct investment from industry leaders. In the coming years, market demand in population-dense Asian Pacific clusters is expected to exceed demand from the mature markets in the United States and Europe. Thus, we examine four emerging clusters in the region. 80 Asia Pacific | Jones Lang LaSalle Emerging China India Indonesia Singapore Established clusters Emerging clusters Tof C
1.4% R&D expenditure (% of GDP, 2007) Emerging cluster China 1,071 Researchers in R&D (per million people, 2007) The People’s Republic of China is quickly emerging as a top destinations for life sciences investment due to its huge market potential (large population, improving public health care systems, increasing healthcare expenditure as a percentage of GDP) and low cost manufacturing sector. Overview 31.0% High technology exports (% overall exports, 2009) 81 Asia Pacific | Jones Lang LaSalle 4.6% Total health expenditure (% of GDP, 2009) China’s pharmaceutical industry has enjoyed massive growth over the past decade. The country’s emergence onto the radar screen of multi-national life science companies parallels its growth into one of the world’s dominant economies with a significant and growing middle class, an increasingly open and inviting marketplace and waves of foreign investors lined up to take part. Certainly, one reason for interest in China was its low-cost manufacturing capabilities. Historically, Western pharmaceutical makers enjoyed a 30 to 50 percent cost savings by relocating the manufacturing of intermediates, APIs, starting materials and some finished drugs to China. The focus is now on 29 World economic forum’s innovation rank (out of 142) expanding capabilities beyond manufacturing into more hightech R&D functions. Multinationals are taking bolder steps as highlighted by AstraZeneca’s recent announcement to invest $200 million on a new plant in China (its biggest-ever investment in one production facility) that will turn out injectables and oral drugs for the domestic market. With the world’s largest population and second-largest economy with a growing middle class, China’s prospective consumer base is unmatched by any country worldwide. Additionally, the Chinese government is trying to entice foreign and domestic investment in a local life sciences industry, spending billions on the advancement of science and technology as outlined early 2011 in the 12th Five-Year Plan. Tof C
Page 1 and 2:
Life sciences cluster report Global
Page 3 and 4:
Introduction A message from Bill Ba
Page 5 and 6:
Revenue growth To increase revenue,
Page 7 and 8:
= $15 billion 7 The drug and pharma
Page 9 and 10:
Manufacturing Office R&D HQ Support
Page 11 and 12:
India ranked third for inward direc
Page 13 and 14:
Conclusion As we emerge from a peri
Page 15 and 16:
United States, Canada, Brazil and P
Page 17 and 18:
4th 13.5% 8th % life science employ
Page 19 and 20:
Bay Area Innovation capital For mor
Page 21 and 22:
Boston Others, however, choose to k
Page 23 and 24:
13th 11.6% 8th % life science emplo
Page 25 and 26:
Los Angeles Innovation capital The
Page 27 and 28:
New York / New Jersey in excess of
Page 29 and 30: 2nd 14.8% 6th % life science employ
Page 31 and 32: Philadelphia Innovation capital Wit
Page 33 and 34: Raleigh Durham The Raleigh-Durham l
Page 35 and 36: 11th 11.9% 8th % life science emplo
Page 37 and 38: San Diego Innovation capital The Sc
Page 39 and 40: Seattle Typically, life sciences te
Page 41 and 42: 12th 11.7% 3rd % life science emplo
Page 43 and 44: Washington DC / Suburban Maryland F
Page 45 and 46: Atlanta In a 2009 study by Georgia
Page 47 and 48: 9th 12.3% 5th % life science employ
Page 49 and 50: 13th 11.6% 7th % life science emplo
Page 51 and 52: 10th 12.1% % life science employmen
Page 53 and 54: Florida Industry framework Intellec
Page 55 and 56: Houston Industry framework Intellec
Page 57 and 58: 6th 13.0% % life science employment
Page 59 and 60: Indianapolis In addition, several i
Page 61 and 62: Minneapolis historically have worke
Page 63 and 64: Canada Industry framework Intellect
Page 65 and 66: 1.1% R&D expenditure (% of GDP, 200
Page 67 and 68: Emerging cluster Puerto Rico Over t
Page 69 and 70: France, Germany, Switzerland and Un
Page 71 and 72: France Pharmaceutical production is
Page 79: United Kingdom Industry framework T
Page 83 and 84: China ■ Zhongguancun (ZGC) Life S
Page 85 and 86: India The life sciences industry is
Page 87 and 88: India To support the distribution c
Page 89 and 90: Indonesia About 35 companies are fo
Page 93 and 94: Singapore Fiscal & political resour
Page 95 and 96: Emerging cluster governments in Asi
Page 97: www.joneslanglasalle.com ©2011 Jon
show all

Global Life Sciences Cluster Report 2011 - Jones Lang LaSalle

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?